Frederic J. Kaye, MD
Dr. Frederic J. Kaye is a cancer specialist, hematologist, and hematology and oncology specialist with a special interest in thoracic malignancies, including lung cancer and malignant pleural mesothelioma. He is a professor of medicine and medical director of thoracic oncology program at University of Florida Health and the director of the lung cancer center within the division of hematology and oncology at the University of Florida Health Cancer Center.
In addition to his clinical care of patients, he is also a professor of medicine and a basic science investigator. His research focus is on lung cancer tumor biology and the use of targeted therapies in treating these challenging diseases. Dr. Kaye is board-certified in Hematology, Internal Medicine, and Oncology.[1]
Education and Career
Dr. Kaye earned his medical degree from the University of Maryland, then went on to complete his internship and residency in Internal Medicine at Mount Sinai Hospital in New York. He remained at Mount Sinai to complete a fellowship in Hematology, then moved on to the National Cancer Institute to complete a fellowship in Oncology.[1]
As a professor of medicine, clinical cancer specialist, and medical director of the thoracic oncology program at the University of Florida Health Cancer Center, Dr. Kaye’s areas of focus include:
- Head and neck cancer
- Lung cancer
- Small-cell lung cancer
- Malignant pleural mesothelioma
- Non-small-cell lung cancer
- Oral cancer
- Salivary gland tumors
- Throat or larynx cancer
- Thyroid cancer
Dr. Kaye is also an elected member of the American Society for Clinical Investigation, the Alpha Omega Alpha medical honor society, and serves as Associate Editor of the Journal of the National Cancer Institute.
Research
Dr. Kaye has led and participated in over 175 published clinical trials and studies investigating issues in both lung cancer and malignant mesothelioma. Some of his notable works include:
• “Targeting EphA2 Using miR-302b Encapsulated-eprhin-A1 Conjugated Liposomal Nanoparticles Inhibits Malignant Pleural Mesothelioma Tumor Growth,” published in the American Journal of Respiratory and Critical Care Medicine.[2]
• “MicroRNA-590 Regulates Tumor Growth by Targeting Receptor Epha2 In Malignant Pleural Mesothelioma,” published in the American Journal of Respiratory and Critical Care Medicine
